Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

BACKGROUND:A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult v...

Full description

Bibliographic Details
Main Authors:	Sodiomon B Sirima, Alfred B Tiono, Alphonse Ouédraogo, Amidou Diarra, André Lin Ouédraogo, Jean Baptiste Yaro, Espérance Ouédraogo, Adama Gansané, Edith C Bougouma, Amadou T Konaté, Youssouf Kaboré, Abdoulaye Traoré, Roma Chilengi, Issiaka Soulama, Adrian J F Luty, Pierre Druilhe, Simon Cousens, Issa Nébié
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2009-10-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC2764341?pdf=render

Internet

http://europepmc.org/articles/PMC2764341?pdf=render

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Internet

Similar Items